journal article·2024-09Open access

Crystal structure of alectinib hydrochloride Type I, C 30 H 35 N 4 O 2 Cl

James A. Kaduk, Megan M. Rost, Anja Dosen, Thomas N. Blanton

Powder Diffraction· Volume 39· Issue 3

Abstract

The crystal structure of alectinib hydrochloride has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Alectinib hydrochloride crystallizes in space group P 2 1 / n (#14) with the following parameters: a = 12.67477(7), b = 10.44076(5), c = 20.38501(12) Å, β = 93.1438(7)°, V = 2693.574(18) Å 3 , and Z = 4 at 295 K. The crystal structure consists of stacks of molecules along the b -axis, and the stacks contain chains of strong N–H⋯Cl hydrogen bonds. One density functional theory calculation moved a proton from an N atom to the Cl, but another calculation yielded a more chemically reasonable result. The powder pattern has been submitted to ICDD for inclusion in the Powder Diffraction File™ (PDF®)
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Synthesis and biological activity · Quinazolinone synthesis and applications · Crystal structures of chemical compounds

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (32)

Show source-provided references
1. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
2. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
3. 10.1007/BF0054909610.1007/BF00549096 ↗
4. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
5. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
6. 2022
7. 2016
8. A New Law of Crystal Morphology Extending the Law of Bravais
9. Bravais · 1866
10. 10.1021/ci049780b10.1021/ci049780b ↗
11. 10.3749/canmin.46.5.150110.3749/canmin.46.5.1501 ↗
12. Tanaka, K. , and Ueto, T. . 2019. “Novel Crystal of Tetracyclic Compound.” European Patent EP3135671 B1.
13. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
14. Crystal Impact. 2023. Diamond. V. 5.0.0. Crystal Impact – Dr. H. Putz & Dr. K. Brandenburg.
15. 2023
16. 2013
17. 10.1107/S002188989800600110.1107/S0021889898006001 ↗
18. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
19. 2022
20. 10.1017/S088571561900081210.1017/S0885715619000812 ↗
21. Tomar, V. S. , Azim, A. , Gupta, N. , Lahiri, S. , and Cabri, W. . 2020. “A Process for Preparing Alectinib or a Pharmaceutically Acceptable Salt Thereof.” United States Patent Application US2020/0140427 A1.
22. Tomar, V. S. , Azim, A. , Gupta, N. , Lahiri, S. , and Cabri, W. . 2019. “A Process for Preparing Alectinib or a Pharmaceutically Acceptable Salt Thereof.” International Patent Application WO2019/008520 A1.
23. 10.1093/nar/gkac95610.1093/nar/gkac956 ↗
24. 10.1063/1.296926010.1063/1.2969260 ↗
25. 10.1063/1.46788210.1063/1.467882 ↗
26. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
27. 10.1021/acs.jctc.2c0095810.1021/acs.jctc.2c00958 ↗
28. 10.3406/bulmi.1907.282010.3406/bulmi.1907.2820 ↗
29. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
30. 10.1002/jcc.2315310.1002/jcc.23153 ↗
31. 10.1107/S160057672100291010.1107/S1600576721002910 ↗
32. 10.1017/S088571561400051710.1017/S0885715614000517 ↗